Qeisari Mehdi; Zerehpoosh Farahnaz Bidari; Abdollahimajd Fahmimeh; Salajeghe Sara
Volume 16, Issue 4 , 2013, , Pages 165-167
Abstract
A 77-year-old Iranian man was visited at the Dermatology Department of Loghman-e Hakim Hospital affiliated with Shahid Beheshti University of Medical Sciences on June 2012 with bilateral, symmetric, raised, violaceous and painless plaques on the nose (both ala nasi), from one year ago. The lesions were ...
Read More
A 77-year-old Iranian man was visited at the Dermatology Department of Loghman-e Hakim Hospital affiliated with Shahid Beheshti University of Medical Sciences on June 2012 with bilateral, symmetric, raised, violaceous and painless plaques on the nose (both ala nasi), from one year ago. The lesions were small at first and then grew gradually larger in size. Systemic symptoms such as fever, weight loss and night sweat were absent. He had no history of systemic disease, bite, trauma, vaccination, or medication. Past medical history was negative except for cataract in several years ago and he was in good health. He had a history of treatment with oral antibiotics without any improvement. Physical examination revealed bilateral, symmetric, indurated, violaceous, non-tender plaques on the nose (both ala nasi) with some scales and follicular accentuation without discharge (Figure 1). Other examinations were normal and laboratory tests revealed no abnormality. A skin biopsy was performed.
Asadi-Kani Zahra; Qeisari Mehdi; Taheri Shahrzad Azizaddini Allahiar; Sarlak Mojdeh
Volume 13, Issue 3 , 2010, , Pages 99-102
Abstract
Leishmaniasis affects 1.5-2 million new cases in the world annually. Two major complications of cutaneous leishamaniasis include diffuse cutaneous leishamaniasis (DCL ) occurring in the setting of deficient cell mediated immunity, typically with HIV infection, and chronic cutaneous leishamaniasis (CCL ...
Read More
Leishmaniasis affects 1.5-2 million new cases in the world annually. Two major complications of cutaneous leishamaniasis include diffuse cutaneous leishamaniasis (DCL ) occurring in the setting of deficient cell mediated immunity, typically with HIV infection, and chronic cutaneous leishamaniasis (CCL ) developing in approximately 4% of L. tropica infections in Iran and Afghanistan which also may complicate vaccination with a live strain of leishmania (leishmanization). The Iran – Iraq war took place in a hyper endemic area of Old-World cutaneous leishmaniasis. We report two Iranian soldiers who were both infected in the battle field and presented several years after the war; one was an HIV positive patient with DCL and the other was a previously leishmaniazed patient with CCL.
Barikbin Behrooz; Qeisari Mehdi; Saeedi Marjan; Esmailiazad Mitra; Moravvej Hamideh; Yousefi Maryam; Ahmadi Amrollah
Volume 13, Issue 1 , 2010, , Pages 16-19
Abstract
Background: Psoriasis is a common inflammatory skin disorder. There has been considerable interest in herbal medicine as a treatment for psoriasis. In a previous study HESA-A, a marine-herbal drug, was found to be beneficial in the treatment of psoriasis vulgaris. The aim of this study was to assess ...
Read More
Background: Psoriasis is a common inflammatory skin disorder. There has been considerable interest in herbal medicine as a treatment for psoriasis. In a previous study HESA-A, a marine-herbal drug, was found to be beneficial in the treatment of psoriasis vulgaris. The aim of this study was to assess the efficacy and tolerability of HESA-A in patients with psoriasis. Methods: Nineteen patients with a mean PASI score of 13.04±6.14 (min=3.90, max=27.70) were recruited to receive daily dosage of 30 mg/kg of HESA-A tablets for at least 4 weeks. The patients were followed every two weeks for determining PASI score changes and drug side effects until the end of the study. Result: At the end of the study, the mean PASI score of the patients reduced to 9.60±5.30 (min=0.90, max=19.1). PASI score reduced in 14 patients (73.7%) and increased in 5 patients (26.3%) during the study. Two patients achieved 75 to 100% improvement in PASI score and two achieved 50 to 75%. In 10 patients (52.6%), 1 to 50% improvement in the PASI score was detected. There was a statically significant correlation between the duration of treatment and PASI improvement. (P-value = 0.024) Conclusion: Although this drug was very safe and tolerable, our study did not find rapid and acceptable efficacy in the treatment of chronic plaque psoriasis as shown in a previous study. According to our findings, HESA-A was more effective when used for a prolonged time and in respect of the safety profile of HESA-A, we can use this drug as a maintenance or adjuvant therapy for chronic plaque psoriasis in longer terms.
Malekzad Farhad; Qeisari Mehdi; Nasiri Soheila; Rahmati-Roudsari Mohammad; Saeedi Marjan; Sarlak Mojdeh
Volume 12, Issue 1 , 2009, , Pages 9-12
Abstract
Background: An elevated homocysteine level is an independent risk factor for cardiovascular disorders. Psoriatic patients have an increased risk of cardiovascular diseases; In addition, hyperhomocysteinemia is a complication of methotrexate treatment. We undertook a study to evaluate the plasma levels ...
Read More
Background: An elevated homocysteine level is an independent risk factor for cardiovascular disorders. Psoriatic patients have an increased risk of cardiovascular diseases; In addition, hyperhomocysteinemia is a complication of methotrexate treatment. We undertook a study to evaluate the plasma levels of homocysteine, vitamin B12 and folate in patients with psoriasis before and after short-term low-dose methotrexate treatment. Methods: Twenty six patients with psoriasis were recruited. The plasma levels of homocysteine, vitamin B12 and folate were evaluated before and 8 weeks after methotrexate therapy (in the peak of methotrexate effect). Results: No significant difference was found between the plasma profile of homocysteine, vitamin B12 and folate before and after methotrexate treatment. Conclusion: In the short-term treatment of psoriasis, methotrexate does not increase homocysteine level.
